{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-044203","form_type":"8-K/A","ticker":"PLSH","cik":"0001552189","company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","filed_at":"2023-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.486653+00:00","generated_at":"2026-06-07T15:35:10.504847+00:00","sec_items":["9.01","2.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Panacea Life Sciences Holdings files N7 Enterprises financials showing losses and going concern","bullets":["N7 had $326k revenue and $82k net loss in 2022; 6mo2023 revenue $1.18M, net loss $147k.","Auditors express substantial doubt about N7's ability to continue as a going concern.","Acquisition consideration: 784 preferred shares convertible into 7.84M common shares of Panacea.","N7 started operations Nov 2022; negative cash flows and accumulated deficit noted.","Pro forma financials combine Panacea and N7 for six months ended June 30, 2023 and year ended Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-044203","json":"https://secwatch.observer/filing/0001493152-23-044203.json","markdown":"https://secwatch.observer/filing/0001493152-23-044203.md","text":"https://secwatch.observer/filing/0001493152-23-044203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1552189/000149315223044203/0001493152-23-044203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1552189/000149315223044203/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:35:10.504847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}